The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases. SpringWorks is the brainchild of Lara Sullivan, a former Pfizer R&D strategy executive who gained Pfizer's ...

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

The internet is full of false claims. Columnist Sam Kirton shares why fact-checking is important, particularly for the rare disease world.

Pfizer has abandoned development of a hemophilia ... Another gene therapy for the rare bleeding disorder was approved last year but has mustered little interest, largely because standard-of ...

Earlier this year, Pfizer had revealed data from the therapy's late-stage study, which showed that the treatment reduced the number of annual bleeding episodes in patients with the rare disorder.

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

“Pfizer Ignite has worked closely with Anokion ... The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes.